AYTU BIOPHARMA INC. news, videos and press releases
For more news please use our advanced search feature.
AYTU BIOPHARMA INC. - More news...
AYTU BIOPHARMA INC. - More news...
- Aytu Announces $20 Million Registered Direct Offering Priced At-the-Market
- Aytu BioScience Expands Its Distribution Rights for Coronavirus 2019 (COVID-19) Point-of-Care Rapid Test to Canada and Mexico
- Aytu BioScience Announces Acceleration of U.S. Availability of COVID-19 IgG/IgM Rapid Test Based on Updated FDA Policy
- Aytu BioScience's Coronavirus Rapid Test Featured on NBC and Fox News (VIDEOS): ''Englewood Company Says It Can Get COVID-19 Test Results in 2-10 Minutes"; "2-Minute COVID-19 Test Results? Denver-Area Company Wants to Deliver That Promise"
- Aytu BioScience Establishes COVID-19 IgG/IgM Rapid Test Product Inquiry Procedure for Healthcare Professionals and Institutions
- Aytu Announces $20 Million Registered Direct Offering Priced At-the-Market
- Aytu Announces $9.0 Million Registered Direct Offering Priced At-the-Market
- Aytu BioScience Secures Exclusive U.S. Distribution Agreement for Coronavirus 2019 (COVID-19) Point-of-Care Rapid Test
- Aytu BioScience Completes Acquisition of Innovus Pharmaceuticals
- Aytu Reports Q2 Revenue of $3.2M, Up 77% Year-over-Year and 121% Sequentially
- Aytu BioScience to Report Fiscal Q2 FY 2020 Results and Business Update
- Aytu BioScience Announces Acceptance of Results of Two Natesto Clinical Studies for Presentation at American Urological Association Annual Scientific Program
- Aytu BioScience Announces Acceptance of Natesto Spermatogenesis Study Results for Presentation at ENDO 2020
- Aytu BioScience and Innovus Pharmaceuticals Announce Effectiveness of Form S-4 Registration Statement Related to Proposed Acquisition of Innovus by Aytu BioScience
- Aytu BioScience and Innovus Pharmaceuticals Announce Filing of Form S-4 Registration Statement Related to Proposed Acquisition of Innovus by Aytu BioScience
- Aytu BioScience Announces Addition of Tuzistra(R) XR to Leading National Pharmacy Benefit Manager's Formulary
- Aytu BioScience Announces Positive Clinical Results from Natesto(R) Spermatogenesis Study
- Aytu BioScience to Announce Results from Natesto(R) Spermatogenesis Study on Thursday, October 17
- Aytu BioScience Acquires $12.4 Million Prescription Product Portfolio
- Aytu BioScience Announces $10 Million Private Placement
- Aytu BioScience and Validus Pharmaceuticals Announce ZolpiMist Co-Promotion Agreement and Launch Into the $163 Million Psychiatry Market
- Aytu BioScience Reports 100% Revenue Growth to $7.3 million in FY 2019
- Aytu BioScience Announces Addition of Natesto(R) to Leading National Pharmacy Benefit Manager’s Formulary; Natesto Added to Commercial Plans Covering Over 30 Million U.S. Lives
- Aytu BioScience to Report Fiscal FY 2019 Results and Business Update
- Aytu BioScience to Present at Ladenburg Thalmann 2019 Healthcare Conference
- Aytu BioScience Announces Definitive Agreement to Acquire Innovus Pharmaceuticals
- Aytu BioScience Announces Availability of the MiOXSYS(R) Male Infertility Test in South Africa
- Aytu BioScience Announces Tuzistra XR Co-Promotion Agreement with Poly Pharmaceuticals
- Aytu BioScience Announces First ZolpiMist(TM) Clinical Study Results Demonstrating More Rapid Sleep Onset with Lingual Spray Zolpidem versus Oral Tablet
- Natesto Spermatogenesis Study Final Results Accepted for Presentation at 'Late-Breaking' Session at the American Society for Reproductive Medicine 75th Annual Scientific Conference